In an effort to combat cancer, Merus N.V. - a clinical-stage immuno-oncology company based in the Netherlands - is developing a pipeline of promising antibody therapeutics. Among its candidates is Zenocutuzumab (MCLA-128), currently in phase 2 clinical trials as a potential treatment option for metastatic breast cancer and castration-resistant prostate cancer. MCLA-128 is also undergoing phase 1/2 clinical trials for the treatment of solid tumors with Neuregulin 1. Other candidates include MCLA-158, which is in phase I clinical trial for the treatment of solid tumors, MCLA-145 in phase 1 clinical trials for the treatment of solid tumors, MCLA-129 in phase 1/2 clinical trials for the treatment of advanced non-small cell lung cancer and other tumors, and ONO-4685 in a Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. Merus N.V. has also partnered with Betta Pharmaceuticals Co. Ltd and Incyte Corporation for the research and development of bispecific antibody candidates, including MCLA-129 and MCLA-145, respectively. The company, founded in 2003, is headquartered in Utrecht, the Netherlands.
Merus's ticker is MRUS
The company's shares trade on the NASDAQ stock exchange
They are based in Utrecht, Netherlands
There are 51-200 employees working at Merus
It is https://merus.nl/
Merus is in the Healthcare sector
Merus is in the Biotechnology industry
The following five companies are Merus's industry peers: